Demographic and Regional Trends of Hypertrophic Cardiomyopathy-Related Mortality in the United States, 1999 to 2019

Background: Hypertrophic cardiomyopathy (HCM)-related mortality has been decreasing within the United States; however, persistent disparities in demographic subsets may exist. In this study, we assessed nationwide trends in mortality related to HCM among people ≥15 years of age in the United States from 1999 to 2019. Methods: Trends in mortality related to HCM were assessed through a cross-sectional analysis of the Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiological Research database. Age-adjusted mortality rates per 1 000 000 people and associated annual percent changes with 95% CIs were determined. Joinpoint regression was used to assess the trends in the overall, demographic (sex, race and ethnicity, age), and regional groups. Results: Between 1999 and 2019, 39 200 HCM-related deaths occurred. In the overall population, age-adjusted mortality rate decreased from 11.2 in 1999 to 5.4 in 2019. Higher mortality rates were observed for males, Black patients, and patients ≥75 years of age. Large metropolitan counties experienced pronounced declines in age-adjusted mortality rate over the study period. In addition, California had the highest overall age-adjusted mortality rate. Conclusions: Over the past 2 decades, HCM-related mortality has decreased overall in the United States. However, demographic and geographic disparities in HCM-related mortality have persisted over time and require further investigation.

[1]  M. Sherrid,et al.  Disease Expression and Outcomes in Black and White Adults With Hypertrophic Cardiomyopathy , 2021, Journal of the American Heart Association.

[2]  M. Khan,et al.  Rural-Urban Differences in Mortality From Ischemic Heart Disease, Heart Failure, and Stroke in the United States , 2021, Circulation. Cardiovascular quality and outcomes.

[3]  D. Kazi,et al.  Rural-Urban Disparities: Diabetes, Hypertension, Heart Disease, and Stroke Mortality Among Black and White Adults, 1999-2018. , 2021, Journal of the American College of Cardiology.

[4]  N. Smedira,et al.  Characteristics and Outcomes of Elderly Patients With Hypertrophic Cardiomyopathy , 2021, Journal of the American Heart Association.

[5]  Matthew W. Martinez,et al.  2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2020, Circulation.

[6]  R. Ferreira,et al.  Coronary microvascular dysfunction in hypertrophic cardiomyopathy: Pathophysiology, assessment, and clinical impact , 2020, Microcirculation.

[7]  E. Ashley,et al.  Temporal Trend of Age at Diagnosis in Hypertrophic Cardiomyopathy , 2020, Circulation. Heart failure.

[8]  E. Ashley,et al.  Association of Race With Disease Expression and Clinical Outcomes Among Patients With Hypertrophic Cardiomyopathy. , 2019, JAMA cardiology.

[9]  B. Maron,et al.  Impact of Sex on Clinical Course and Survival in the Contemporary Treatment Era for Hypertrophic Cardiomyopathy , 2019, Journal of the American Heart Association.

[10]  M. Michels,et al.  Sex differences in hypertrophic cardiomyopathy: new insights , 2019, Current opinion in cardiology.

[11]  C. Yancy,et al.  Cardiovascular Health in African Americans: A Scientific Statement From the American Heart Association , 2017, Circulation.

[12]  A. Hughes,et al.  Mechanisms of Myocardial Ischemia in Hypertrophic Cardiomyopathy , 2016, Journal of the American College of Cardiology.

[13]  Deepak L. Bhatt,et al.  Sex and Race/Ethnicity Differences in Implantable Cardioverter-Defibrillator Counseling and Use Among Patients Hospitalized With Heart Failure: Findings from the Get With The Guidelines-Heart Failure Program , 2016, Circulation.

[14]  M. Maron,et al.  Occurrence of Clinically Diagnosed Hypertrophic Cardiomyopathy in the United States. , 2016, The American journal of cardiology.

[15]  B. Maron,et al.  Hypertrophic Cardiomyopathy in Children, Adolescents, and Young Adults Associated With Low Cardiovascular Mortality With Contemporary Management Strategies , 2016, Circulation.

[16]  S. Frisbee,et al.  Changes in Cardiovascular Health in the United States, 2003–2011 , 2015, Journal of the American Heart Association.

[17]  M. Link,et al.  Hypertrophic Cardiomyopathy in Adulthood Associated With Low Cardiovascular Mortality With Contemporary Management Strategies. , 2015, Journal of the American College of Cardiology.

[18]  Barry J Maron,et al.  New perspectives on the prevalence of hypertrophic cardiomyopathy. , 2015, Journal of the American College of Cardiology.

[19]  Barry J Maron,et al.  Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. , 2014, Journal of the American College of Cardiology.

[20]  Deborah D Ingram,et al.  2013 NCHS Urban-Rural Classification Scheme for Counties. , 2014, Vital and health statistics. Series 2, Data evaluation and methods research.

[21]  B. Gersh,et al.  Survival After Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy , 2012, Circulation.

[22]  L. Jordaens,et al.  Outcome and Complications After Implantable Cardioverter Defibrillator Therapy in Hypertrophic Cardiomyopathy: Systematic Review and Meta-Analysis , 2012, Circulation. Heart failure.

[23]  H. Krumholz,et al.  Racial disparities in health literacy and access to care among patients with heart failure. , 2011, Journal of cardiac failure.

[24]  Udo Sechtem,et al.  Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. , 2010, Journal of the American College of Cardiology.

[25]  G. Bonsel,et al.  Risk stratification for sudden cardiac death in hypertrophic cardiomyopathy: systematic review of clinical risk markers. , 2010, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[26]  V. Positano,et al.  Usefulness of delayed enhancement by magnetic resonance imaging in hypertrophic cardiomyopathy as a marker of disease and its severity. , 2010, The American journal of cardiology.

[27]  M. Sheppard,et al.  Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy using cardiovascular magnetic resonance , 2010 .

[28]  Barry J Maron,et al.  The case for myocardial ischemia in hypertrophic cardiomyopathy. , 2009, Journal of the American College of Cardiology.

[29]  A. Tajik,et al.  Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. , 2005, Journal of the American College of Cardiology.

[30]  M. Link,et al.  Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy. , 2005, Journal of the American College of Cardiology.

[31]  B. Maron,et al.  Clinical course of hypertrophic cardiomyopathy with survival to advanced age. , 2003, Journal of the American College of Cardiology.

[32]  G Thiene,et al.  Hypertrophic cardiomyopathy and sudden death in the young: pathologic evidence of myocardial ischemia. , 2000, Human pathology.

[33]  H M Rosenberg,et al.  Age standardization of death rates: implementation of the year 2000 standard. , 1998, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[34]  D. D. Ingram,et al.  NCHS urban-rural classification scheme for counties. , 2012, Vital and health statistics. Series 2, Data evaluation and methods research.

[35]  Jay J. Shen,et al.  Factors underlying racial disparities in hospital care of congestive heart failure. , 2007, Ethnicity & disease.